Taiwan-made flu vaccine cracks Japan market Publication Date: September 9, 2015 Source: Taiwan Today Taiwan-made flu vaccine cracks Japan market Adimmune Corp. Chairman Chan Chi-shean and Japan Daiichi-Sankyo's Takeshi Ogita seal a landmark flu vaccine deal Sept. 8 in Taipei City. (CNA) A Taiwan-developed influenza vaccine is set to enter the Japanese market, setting a new milestone in global growth for the country's pharmaceutical sector. Under a Sept. 8 agreement between Taichung City-based Adimmune Corp. and Tokyo-headquartered Daiichi-Sankyo Co. Ltd., the former will provide the latter with four-strain vaccine solutions equivalent to 4 million doses annually over five years. Dr. Chan Chi-shean, chairman of Adimmune, said the tie-up is another major gain for the company following its EU Pharmaceutical Inspection Convention and Co-operation Scheme certification. "We are looking forward to joining hands with Japan's second largest pharmaceutical company on building vertical integration in the supply of high-quality flu vaccines."By boosting concerted efforts in the areas of manufacturing, quality and R&D, we have every reason to believe this collaboration will facilitate access to other markets around the world."In addition to the EU and Japan, Adimmune flu vaccines have been approved by South Korea's food and drug administration. The company is also working to enter the mainland Chinese market by year-end."We are planning to team up with regional channel operators after obtaining the green light from Beijing," an Adimmune official said. "Given annual demand of 45 million doses and 3 percent vaccination coverage in mainland China, we forecast business to reach new heights on the back of this potential-laden pact." (YHC-JSM)
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment